First-in-human study targets advanced lung cancer
May 23, 2018
For people with advanced lung cancer, clinical trials open up new treatment options and offer access to promising new therapies. At Providence Cancer Institute, 19 studies of novel lung cancer therapies are open to patients now, including this new immunotherapy study for people with advanced non-small cell lung cancer:
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
The study agent, JNJ-61186372, is an antibody that recognizes and binds to two cancer-growth receptors: EGFR and cMet. The hope is that targeting these receptors will help deactivate them and prevent the cancer from growing. The study will help establish the optimal dosing regimen and evaluate responses to the drug. Providence is one of seven centers in the U.S. offering this study.
Read more about this study in Immuno-Oncology News.
Get study details.
New research studies are added frequently. Please visit our website to see all lung cancer studies currently open at Providence Cancer Institute. For more information or to enroll a patient, call our Clinical Research office at 503-215-2614.
Multidisciplinary lung cancer management
The Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management. Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical techniques, radiation, chemotherapy, targeted therapy and immunotherapy agents, and tissue banking.
Rachel Sanborn, M.D., co-director of the program, is the lead investigator of the featured study. Her research focuses on studying new agents or combinations of treatments for lung cancer, mesothelioma and other thoracic tumors.
See more studies
See all lung cancer studies currently open to patients.
See all studies in all cancer types (nearly 150 studies are currently open) at Providence Cancer Institute.